Mutation frequency of homologous recombination repair genes in prostate adenocarcinomas

• Published in: Magyar onkologia Vol. 68; no. 2; p. 137
• Main Authors: Melegh, Zsombor, Csernák, Erzsébet, Kohánka, Andrea, Rubovszkyné Gallai, Mónika, Bencze, Eszter, Szőke, Melinda, Pap, Luca, Simon, Andrea, Küronya, Zsófia, Biró, Krisztina, Géczi, Lajos, Tóth, Erika
• Format: Journal Article
• Language: Hungarian
• Published: Hungary 16.07.2024
• Subjects: Adenocarcinoma - drug therapy; Adenocarcinoma - genetics; Adenocarcinoma - pathology; Aged; Biomarkers, Tumor - genetics; BRCA1 Protein - genetics; BRCA2 Protein - genetics; Humans; Male; Middle Aged; Mutation; Mutation Rate; Poly(ADP-ribose) Polymerase Inhibitors - therapeutic use; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Recombinational DNA Repair - genetics

The best predictive marker for the expected efficacy of PARP inhibitor therapy is mutations in BRCA1/2 or other homologous recombination repair genes. These tests are part of routine molecular pathology diagnostics. Among 281 patients with prostate adenocarcinoma, somatic pathogenic mutations in one...